Fig. 7.

BBSKE and oxaliplatin combination inhibited GC-PDO growth with increased apoptosis and decreased TrxR1 activity. a Representative morphology of GC-PDO treated with BBSKE and oxaliplatin alone or in combination (scale bars, 20 μm). (b-e) GC-PDO were pretreated with BBSKE and oxaliplatin alone or in combination for 24 h. The percentage of cell apoptosis was determined by flow cytometry (b) and the percentage of apoptotic cells was calculated (c). The cell viability was determined by CCK8 assay (d) and the TrxR1 activity was measured by endpoint insulin reduction assay (e). Data represent similar results from three independent experiments. (* p < 0.05, ** p < 0.01)